These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


311 related items for PubMed ID: 3102046

  • 1. In vitro differentiation of T-cells capable of mediating the regression of established syngeneic tumors in mice.
    Shu S, Chou T, Rosenberg SA.
    Cancer Res; 1987 Mar 01; 47(5):1354-60. PubMed ID: 3102046
    [Abstract] [Full Text] [Related]

  • 2. Cellular basis of immunologic interactions in adoptive T cell therapy of established metastases from a syngeneic murine sarcoma.
    Ward BA, Shu S, Chou T, Perry-Lalley D, Chang AE.
    J Immunol; 1988 Aug 01; 141(3):1047-53. PubMed ID: 3260908
    [Abstract] [Full Text] [Related]

  • 3. Cellular interactions and the role of interleukin 2 in the expression and induction of immunity against a syngeneic murine sarcoma.
    Chou T, Shu S.
    J Immunol; 1987 Sep 15; 139(6):2103-9. PubMed ID: 2957448
    [Abstract] [Full Text] [Related]

  • 4. Adoptive immunotherapy of a newly induced sarcoma: immunologic characteristics of effector cells.
    Shu S, Rosenberg SA.
    J Immunol; 1985 Oct 15; 135(4):2895-903. PubMed ID: 2411817
    [Abstract] [Full Text] [Related]

  • 5. Phenotype analyses and cellular mechanisms of the pre-effector T-lymphocyte response to a progressive syngeneic murine sarcoma.
    Sakai K, Chang AE, Shu SY.
    Cancer Res; 1990 Jul 15; 50(14):4371-6. PubMed ID: 2114215
    [Abstract] [Full Text] [Related]

  • 6. Generation from tumor-bearing mice of lymphocytes with in vivo therapeutic efficacy.
    Shu SY, Chou T, Rosenberg SA.
    J Immunol; 1987 Jul 01; 139(1):295-304. PubMed ID: 2953816
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Requirements for the generation of a Lyt-2+ T-cell proliferative response to a syngeneic tumor in the absence of L3T4+ T-cells.
    Kern DE, Klarnet JP, Cheever MA, Greenberg PD.
    Cancer Res; 1990 Oct 01; 50(19):6256-63. PubMed ID: 2144789
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2.
    Yoshizawa H, Chang AE, Shu S.
    J Immunol; 1991 Jul 15; 147(2):729-37. PubMed ID: 1830072
    [Abstract] [Full Text] [Related]

  • 15. Importance of Lyt-2+ T-cells in the resistance of melphalan-cured MOPC-315 tumor bearers to a challenge with MOPC-315 tumor cells.
    Barker E, Mokyr MB.
    Cancer Res; 1988 Sep 01; 48(17):4834-42. PubMed ID: 3261626
    [Abstract] [Full Text] [Related]

  • 16. Some characteristics of the cyclophosphamide-induced immunopotentiating cells in the spleen of mice bearing a large MOPC-315 tumor.
    Mokyr MB, Ye QW.
    Cancer Res; 1985 Oct 01; 45(10):4932-9. PubMed ID: 4027979
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Autoimmune thyroiditis induced in mice depleted of particular T cell subsets. I. Requirement of Lyt-1 dull L3T4 bright normal T cells for the induction of thyroiditis.
    Sugihara S, Izumi Y, Yoshioka T, Yagi H, Tsujimura T, Tarutani O, Kohno Y, Murakami S, Hamaoka T, Fujiwara H.
    J Immunol; 1988 Jul 01; 141(1):105-13. PubMed ID: 2967864
    [Abstract] [Full Text] [Related]

  • 20. Mechanism of tumor rejection in anti-CD3 monoclonal antibody-treated mice.
    Ellenhorn JD, Schreiber H, Bluestone JA.
    J Immunol; 1990 Apr 01; 144(7):2840-6. PubMed ID: 1969454
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 16.